Clinical Trials Logo

Clinical Trial Summary

The aim of the study is to assess the efficacy and safety of an oral regimen of fexinidazole (once daily for 10 days) in the treatment of stage 1 and stage 2 T.b. gambiense sleeping sickness in children at least 6 years old and over 20 kg bodyweight.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02184689
Study type Interventional
Source Drugs for Neglected Diseases
Contact
Status Completed
Phase Phase 2/Phase 3
Start date May 3, 2014
Completion date June 27, 2017

See also
  Status Clinical Trial Phase
Completed NCT01685827 - Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2 Phase 2/Phase 3
Completed NCT02169557 - Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study Phase 2/Phase 3